Page 2 - Affimed News Today

StockNews.com started coverage on shares of Affimed (NASDAQ:AFMD – Free Report) in a report released on Saturday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Other analysts also recently issued reports about the stock. Truist Financial cut their price objective on shares of Affimed from $8.00 to $6.00 and set a […]

Analysts’ new coverage for Saturday, December 9th: StockNews.com started coverage on shares of Affimed (NASDAQ:AFMD). StockNews.com issued a sell rating on the stock. StockNews.com initiated coverage on shares of Air T (NASDAQ:AIRT). The firm issued a hold rating on the stock. StockNews.com began coverage on shares of American National Bankshares (NASDAQ:AMNB). StockNews.com issued a sell […]

Affimed (NASDAQ:AFMD – Get Free Report) has been given an average rating of “Moderate Buy” by the eight brokerages that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12-month target price among analysts that have […]

Affimed N.V. (NASDAQ:AFMD) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Good day, everyone, and welcome to Affimed N.V. Third Quarter 2023 Earnings and Business Update Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there’ll be a question-and-answer session. [Operator Instructions]. Please be advised that today’s […]

StockNews.com began coverage on shares of Affimed (NASDAQ:AFMD – Free Report) in a research report report published on Monday. The firm issued a sell rating on the biopharmaceutical company’s stock. Several other research firms have also commented on AFMD. HC Wainwright reiterated a buy rating and issued a $5.00 target price on shares of Affimed […]

StockNews.com assumed coverage on shares of Affimed (NASDAQ:AFMD – Free Report) in a report released on Sunday. The firm issued a sell rating on the biopharmaceutical company’s stock. A number of other equities research analysts have also weighed in on AFMD. Berenberg Bank restated a buy rating and set a $6.00 price objective on shares […]

Shares of Affimed (NASDAQ:AFMD – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the eight brokerages that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month price objective among […]

Affimed (NASDAQ:AFMD – Get Free Report) was the recipient of a significant decrease in short interest during the month of September. As of September 30th, there was short interest totalling 2,160,000 shares, a decrease of 8.9% from the September 15th total of 2,370,000 shares. Based on an average daily volume of 485,400 shares, the days-to-cover […]

StockNews.com began coverage on shares of Affimed (NASDAQ:AFMD – Free Report) in a research note released on Wednesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock. AFMD has been the subject of several other reports. Truist Financial reduced their target price on Affimed from $8.00 to $6.00 and set a buy […]

StockNews.com began coverage on shares of Affimed (NASDAQ:AFMD – Free Report) in a report released on Wednesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock. Several other equities research analysts have also recently commented on AFMD. Truist Financial lowered their price target on Affimed from $8.00 to $6.00 and set a […]